Evidence map›Paper›PMID 42589474›Full record

ArticleInternational journal of molecular sciences2026

Identifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational Clinical Applications in Lung Adenocarcinoma.

Xueyao Chen, Tongxin Lv, Yang Wu, Fangfang Fan, Shaobo Kang, Renjie Dou, Wanmei Zhang, Dongxue Li, Rui Li, Yanyan Ping

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xueyao ChenCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Tongxin LvCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Yang WuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Fangfang FanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Shaobo KangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Renjie DouCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Wanmei ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Dongxue LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Rui LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Yanyan PingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.ORCID 0000-0002-1810-1200

Funding

Heilongjiang Provincial Postdoctoral Science Foundation LBH-Q20147National Natural Science Foundation of China 32170675
6 · The paper itself

Abstract

Dynamic transcriptomic remodeling of epithelial cells represents a critical hallmark of lung adenocarcinoma (LUAD) progression, yet epithelial-cell progression signatures (ECPSs) linked to this process remain incompletely characterized, impeding our understanding of malignant LUAD transformation. Here, we performed a multi-resolution multi-omics study and identified two functionally opposing ECPSs: a Cancer-Promoting Signature (CPS) and a Cancer-Suppressing Signature (CSS). The CPS was progressively upregulated from normal to early- and advanced-stage lesions, while the CSS was gradually downregulated, and both were validated by multi-resolution transcriptomic data. Both the CPS and CSS demonstrated robust diagnostic value for LUAD, particularly in early-stage detection (median AUC > 0.95). In seven independent validation cohorts, the CPS and CSS served as robust prognostic risk and protective factors, respectively. Their combination could better stratify LUAD patients into distinct prognostic subgroups, with the CPS

Indexed as

Adenocarcinoma of LungEpithelial CellsLung NeoplasmsTranscriptomeBiomarkers, TumorDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMultiomicsPrognosisTranslational Research, BiomedicalTumor MicroenvironmentBiomarkers, Tumorcancer-promoting signaturecancer-suppressing signatureclinical applicationepithelial-cell progression signaturelung adenocarcinomamulti-omics analysis

Identifiers

PMID42589474
PMCPMC13466838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.